Study identifier:D910GC00001
ClinicalTrials.gov identifier:NCT04592913
EudraCT identifier:2019-001555-40
CTIS identifier:2023-507338-26-00
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)
Gastrointestinal Neoplasms
Phase 3
No
Durvalumab, FLOT chemotherapy
All
957
Interventional
18 Years - 200 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Mar 2025 by AstraZeneca
AstraZeneca
-
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
This study investigates treatment of durvalumab or placebo therapy combined with FLOT chemotherapy (flurouroacil + leucovorin + oxaliplatin + docetaxel) given before surgery (neoadjuvant) and durvalumab or placebo therapy combined with FLOT chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer, and also to better understand the studied disease and associated health problems.
Location
Location
Taipei, Taiwan, Province of China, 112
Location
Taoyuan City, Taiwan, Province of China, 333
Location
kaohsiung, Taiwan, Province of China, 807
Location
Tainan City, Taiwan, Province of China, 70403
Location
Seoul, Republic of Korea, 03080
Location
Kecskemét, Hungary, 6000
Location
Szekszárd, Hungary, 7100
Location
Szolnok, Hungary, 5004
Arms | Assigned Interventions |
---|---|
Placebo Comparator: Arm B placebo product and FLOT chemotherapy | Drug: FLOT chemotherapy A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel |
Experimental: Arm A Durvalumab and FLOT chemotherapy | Drug: Durvalumab Human monoclonal antibody Drug: FLOT chemotherapy A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.